Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device
- PMID: 38243008
- PMCID: PMC10799009
- DOI: 10.1038/s41598-024-51766-5
Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device
Erratum in
-
Author Correction: Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device.Sci Rep. 2024 Nov 21;14(1):28878. doi: 10.1038/s41598-024-79454-4. Sci Rep. 2024. PMID: 39572620 Free PMC article. No abstract available.
Abstract
This study aimed to validate a wearable device's walking speed estimation pipeline, considering complexity, speed, and walking bout duration. The goal was to provide recommendations on the use of wearable devices for real-world mobility analysis. Participants with Parkinson's Disease, Multiple Sclerosis, Proximal Femoral Fracture, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure, and healthy older adults (n = 97) were monitored in the laboratory and the real-world (2.5 h), using a lower back wearable device. Two walking speed estimation pipelines were validated across 4408/1298 (2.5 h/laboratory) detected walking bouts, compared to 4620/1365 bouts detected by a multi-sensor reference system. In the laboratory, the mean absolute error (MAE) and mean relative error (MRE) for walking speed estimation ranged from 0.06 to 0.12 m/s and - 2.1 to 14.4%, with ICCs (Intraclass correlation coefficients) between good (0.79) and excellent (0.91). Real-world MAE ranged from 0.09 to 0.13, MARE from 1.3 to 22.7%, with ICCs indicating moderate (0.57) to good (0.88) agreement. Lower errors were observed for cohorts without major gait impairments, less complex tasks, and longer walking bouts. The analytical pipelines demonstrated moderate to good accuracy in estimating walking speed. Accuracy depended on confounding factors, emphasizing the need for robust technical validation before clinical application.Trial registration: ISRCTN - 12246987.
© 2024. The Author(s).
Conflict of interest statement
A. Mueller and F. Kluge are employees of, and may hold stock in, Novartis. B. Eskofier reports consulting activities with adidas AG, Siemens AG, Siemens Healthineers AG, WSAudiology GmbH outside of the study. He is a shareholder in Portabiles HealthCare Technologies GmbH. In addition, B. Eskofier holds a patent related to gait assessment. H. Sillén is an employee of, and may hold stock in, AstraZeneca. L. Palmerini and L. Chiari are co-founders and own shares of mHealth Technologies (
Figures







References
-
- Jehu, D. A. et al. Risk factors for recurrent falls in older adults: A systematic review with meta-analysis. Maturitas144, 23–28 (2021). - PubMed
-
- Walsh, J. A. et al. Gait speed and adverse outcomes following hospitalised exacerbation of COPD. Eur. Respir. J.58, 2004047 (2021). - PubMed
-
- Cameron, M. H. & Nilsagard, Y. Balance, gait, and falls in multiple sclerosis. Handb. Clin. Neurol.159, 237–250 (2018). - PubMed
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources